Evidence map›Paper›PMID 40971752›Full record

ArticleJCO precision oncology2025

Prognostic Significance of

Ruben Raychaudhuri, Isla P Garraway, Kara N Maxwell, Matt Rettig, Heena Desai, Martin W Schoen, Michael T Schweizer, Himisha Beltran, Peter S Nelson, Bruce Montgomery

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JCO precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ruben RaychaudhuriDivision of Hematology and Oncology, University of Washington, VA Puget Sound HCS, Seattle, WA.ORCID 0000-0001-6587-4954
Isla P GarrawayDavid Geffen School of Medicine, University of California, Los Angeles, CA.
Kara N MaxwellDepartment of Medicine, Hematology-Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Matt RettigDavid Geffen School of Medicine, University of California, Los Angeles, CA.
Heena DesaiDepartment of Medicine, Hematology-Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Martin W SchoenSaint Louis Veterans Affairs Medical Center, Saint Louis, MO.ORCID 0000-0001-6388-5553
Michael T SchweizerDivision of Hematology and Oncology, University of Washington, VA Puget Sound HCS, Seattle, WA.
Himisha BeltranDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.ORCID 0000-0003-3259-2226
Peter S NelsonDivision of Hematology and Oncology, University of Washington, VA Puget Sound HCS, Seattle, WA.ORCID 0000-0002-5451-5726
Bruce MontgomeryDivision of Hematology and Oncology, University of Washington, VA Puget Sound HCS, Seattle, WA.ORCID 0000-0003-4459-0295

Funding

TRANSCRIPTOME AND PROTEOME STRATIFICATION OF PROSTATE ADENOCARCINOMA PHENOTYPESP50CA097186 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI PETER S NELSON · 2002 to 2026
$58.1M
TRAINING IN CANCER BIOLOGY &TRANSPLANTATIONT32CA009515 · NCI · UNIVERSITY OF WASHINGTON · PI NANCY ELLEN DAVIDSON, Effie W Petersdorf · 1985 to 2026
$16.2M
Molecular mechanisms underlying lineage plasticity in prostate cancerR37CA241486 · NCI · DANA-FARBER CANCER INST · PI Himisha Beltran · 2020 to 2026
$4.1M
NCI NIH HHS P50 CA097186NCI NIH HHS R37 CA241486NCI NIH HHS T32 CA009515
6 · The paper itself

Abstract

purposeEmerging evidence suggests that

methodsWe analyzed whether

resultsThe primary outcome was overall survival (OS) from onset of metastatic castration-resistant prostate cancer (mCRPC), as well as OS from initiation of life-prolonging therapy other than androgen deprivation therapy, and time to development of mCRPC. Eighty-seven (3.5%) of the 2,512 included patients had an

conclusionIn this large, real-world cohort of men with mCRPC,

Indexed as

Prostatic NeoplasmsProstatic Neoplasms, Castration-ResistantRetinoblastoma Binding ProteinsUbiquitin-Protein LigasesAgedHumansMaleMiddle AgedNeoplasm MetastasisPrognosisRetrospective StudiesRB1 protein, humanRetinoblastoma Binding ProteinsUbiquitin-Protein Ligases

Identifiers

PMID40971752
PMCPMC12453595

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.